First Western Trust Bank Decreases Stock Holdings in Johnson & Johnson (NYSE:JNJ)

First Western Trust Bank cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 19,455 shares of the company’s stock after selling 181 shares during the period. First Western Trust Bank’s holdings in Johnson & Johnson were worth $2,814,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in JNJ. Principal Financial Group Inc. boosted its holdings in Johnson & Johnson by 10.5% in the 3rd quarter. Principal Financial Group Inc. now owns 3,472,312 shares of the company’s stock worth $562,723,000 after buying an additional 329,473 shares during the last quarter. United Bank boosted its stake in shares of Johnson & Johnson by 5.6% in the third quarter. United Bank now owns 3,788 shares of the company’s stock worth $614,000 after acquiring an additional 202 shares during the last quarter. Resurgent Financial Advisors LLC increased its position in shares of Johnson & Johnson by 10.1% during the third quarter. Resurgent Financial Advisors LLC now owns 13,297 shares of the company’s stock worth $2,155,000 after purchasing an additional 1,217 shares in the last quarter. Royal London Asset Management Ltd. lifted its holdings in Johnson & Johnson by 2.0% in the 3rd quarter. Royal London Asset Management Ltd. now owns 1,626,795 shares of the company’s stock valued at $263,638,000 after purchasing an additional 31,334 shares in the last quarter. Finally, Quantinno Capital Management LP boosted its stake in Johnson & Johnson by 29.0% during the 3rd quarter. Quantinno Capital Management LP now owns 219,599 shares of the company’s stock worth $35,588,000 after purchasing an additional 49,307 shares during the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Up 2.9 %

NYSE:JNJ opened at $159.90 on Friday. Johnson & Johnson has a 52 week low of $140.68 and a 52 week high of $169.99. The stock’s fifty day moving average is $159.63 and its two-hundred day moving average is $156.01. The stock has a market capitalization of $385.33 billion, a price-to-earnings ratio of 24.04, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Johnson & Johnson’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the business posted $2.29 EPS. Research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current year.

Insider Activity

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at approximately $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the sale, the vice president now owns 21,001 shares in the company, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 0.16% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. Barclays increased their target price on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research report on Tuesday, January 28th. Royal Bank of Canada reissued an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a research note on Wednesday. Bank of America upped their price target on Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Finally, Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Nine equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.